AIM:AGL

Stock Analysis Report

Executive Summary

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products.

Snowflake

Fundamentals

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has ANGLE's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.3%

AGL

-2.1%

GB Medical Equipment

1.9%

GB Market


1 Year Return

81.6%

AGL

33.1%

GB Medical Equipment

2.4%

GB Market

Return vs Industry: AGL exceeded the UK Medical Equipment industry which returned 33.1% over the past year.

Return vs Market: AGL exceeded the UK Market which returned 2.4% over the past year.


Shareholder returns

AGLIndustryMarket
7 Day1.3%-2.1%1.9%
30 Day-2.5%-0.7%-1.1%
90 Day15.3%7.6%-1.8%
1 Year81.6%81.6%35.8%33.1%7.4%2.4%
3 Year12.9%12.9%48.9%41.2%18.2%3.7%
5 Year-7.6%-7.6%91.4%74.7%35.7%6.1%

Price Volatility Vs. Market

How volatile is ANGLE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ANGLE undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: AGL (£0.79) is trading below our estimate of fair value (£4.69)

Significantly Undervalued: AGL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AGL is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AGL is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate AGL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGL is overvalued based on its PB Ratio (5.9x) compared to the GB Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is ANGLE forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-5.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGL's revenue (74.5% per year) is forecast to grow faster than the UK market (3.9% per year).

High Growth Revenue: AGL's revenue (74.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: AGL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ANGLE performed over the past 5 years?

-24.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AGL is unprofitable, and losses have increased over the past 5 years at a rate of -24.2% per year.

Accelerating Growth: Unable to compare AGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.5%).


Return on Equity

High ROE: AGL has a negative Return on Equity (-46.19%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: AGL is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AGL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is ANGLE's financial position?


Financial Position Analysis

Short Term Liabilities: AGL's short term assets (£14.8M) exceeds its short term liabilities (£3.7M)

Long Term Liabilities: AGL has no long term liabilities


Debt to Equity History and Analysis

Debt Level: AGL is debt free.

Reducing Debt: AGL had no debt 5 years ago.


Balance Sheet

Inventory Level: AGL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AGL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AGL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.5% each year


Next Steps

Dividend

What is ANGLE's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage1.7%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate AGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AGL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGL's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of ANGLE's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Andrew David Newland (57yo)

0yrs

Tenure

UK£403,000

Compensation

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu ...


CEO Compensation Analysis

Compensation vs. Market: Andrew David's total compensation ($USD517.20K) is about average for companies of similar size in the UK market ($USD646.82K).

Compensation vs Earnings: Andrew David's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: AGL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

8.2yrs

Average Tenure

57yo

Average Age

Experienced Board: AGL's board of directors are considered experienced (8.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Andrew David Newland (57yo)

    Founder

    • Tenure: 0yrs
    • Compensation: UK£403.00k
  • Ian Griffiths (54yo)

    CFO, Finance Director

    • Tenure: 15.6yrs
    • Compensation: UK£258.00k
  • Daniel O'Shannessy

    Chief Scientific Officer

    • Tenure: 1.8yrs
  • Paul Smith

    VP & Chief Executive Officer of ANGLE Biosciences Inc

    • Tenure: 1.9yrs
  • Martin Cooke (50yo)

    Director of Manufacturing & Regulatory Affairs

    • Tenure: 1.8yrs
  • Michael O'Brien

    Business Development Director

    • Tenure: 5.9yrs
  • Greg Shaw

    Scientific Advisor & Member of Scientific Advisory Board

    • Tenure: 0yrs

Board Members

  • Harold Swerdlow

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Garth Selvey (70yo)

    Non-Executive Chairman

    • Tenure: 12.1yrs
    • Compensation: UK£23.00k
  • Andrew David Newland (57yo)

    Founder

    • Tenure: 0yrs
    • Compensation: UK£403.00k
  • Ian Griffiths (54yo)

    CFO, Finance Director

    • Tenure: 15.6yrs
    • Compensation: UK£258.00k
  • Ashok Venkitaraman

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Brian Howlett (74yo)

    Non- Executive & Senior Independent Director

    • Tenure: 0.8yrs
    • Compensation: UK£23.00k
  • Clive Stanway

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Adrian Newland

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • George Hvichia (57yo)

    Member of Scientific Advisory Board

    • Tenure: 1.8yrs
  • Jim Reuben

    Member of Scientific Advisory Board

    • Tenure: 4.3yrs
  • Greg Shaw

    Scientific Advisor & Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

ANGLE plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ANGLE plc
  • Ticker: AGL
  • Exchange: AIM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£136.387m
  • Shares outstanding: 172.64m
  • Website: https://www.angleplc.com

Number of Employees


Location

  • ANGLE plc
  • The Surrey Research Park
  • 10 Nugent Road
  • Guildford
  • Surrey
  • GU2 7AF
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2004
ANPC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2004
DWVDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2004
ANPC.YOTCPK (Pink Sheets LLC)SPONSONRED ADRUSUSDOct 2014

Biography

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests rare circulating tum ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 20:36
End of Day Share Price2019/10/16 00:00
Earnings2019/04/30
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.